PRE Earnings
Tuesday, May 12 2026
EPS Estimate
$-0.49
$-0.49 – $-0.49
Revenue Estimate
$38M
Current Price
$18.33
Our Position
bullishIM8 brand hits $120M ARR in first year
The IM8 launch has transformed Prenetics from a COVID-testing relic into a recurring-revenue consumer health play with a clean balance sheet. Sequential acceleration in Q4 and strong ARR suggest the brand has real traction, while the Tencent exit gives management dry powder to scale without dilution risk.
Watch: Watch whether IM8 can sustain ARR growth into Q1 2026 and how management deploys its $171 million cash pile — organic reinvestment or M&A will signal confidence in the model's staying power.
Data Signal Summary
1 bullish
1 bearish
Put/call 0.3 (bullish skew)
Price downtrend
Key Context
Price Trend
downtrend
From 52w High
-7.2%
Analyst Target (mean)
$31 $29–$36 +70%
Options P/C Ratio
0.34
Est. Dispersion
0% 1 analysts
Fund Convergence
moderate Renaissance, Citadel
Explore more
